Skip to content
Back to Investors
O

OrbiMed

Venture Capital

Portfolio

2

companies

By category

  • BioTech£376M

By location

  • London£376M

Portfolio companies

CHARM Therapeutics

CHARM Therapeutics

Discovering small molecule therapeutics through proprietary 3D deep-learning protein-ligand technology.

VB

Verdiva Bio

Verdiva Bio develops next-generation oral therapies and combination treatments for obesity.


Team

RG

Rishi Gupta

Partner


Recent investments

Series A
$411M

The Series A round was co-led by Forbion and General Atlantic to support clinical trials and portfolio expansion.

"People living with obesity and its complications deserve better options at each stage of their treatment journey. These include oral therapies with less frequent dosing regimens, which have the potential for improved efficacy and tolerability, and innovative combination therapies for healthier weight loss and—equally importantly—maintenance of metabolically healthy weight. We created Verdiva Bio to accelerate the development of differentiated medicines that address these significant unmet medical needs."
— Khurem Farooq, Founder